|
|
|
|
|
|
|
programs to train new scientists and develop new scientific methods and models will be key to our future success. |
|
|
|
 |
|
|
|
|
1. J. A. DiMasi, R. W. Hansen, and L. Lasagna. Cost of innovation in the pharmaceutical industry, J. Health Economics 10: 107142, 1992. |
|
|
|
|
|
|
|
|
2. C. K. Prahalad and G. Hamel. The core competence of the corporation, Harvard Business Rev. 7991, 1990. |
|
|
|
|
|
|
|
|
3. M. F. Williams, G. E. Dukes, W. Heizer, Y. Han, D. J. Hermann, T. Lampkin, and L. J. Hak. Influence of gastrointestinal site of drug delivery on the absorption characteristics of ranitidine. Pharm. Res. 9: 11901194, 1992. |
|
|
|
|
|
|
|
|
4. K. M. Koch, A. F. Parr, J. J. Tomlinson, E. P. Sandefer, G. A. Digenis, K. H. Donn, and J. R. Powell. Effect of sodium acid pyrophosphate on ranitidine bioavailability and gastrointestinal transit time. Pharm. Res. 10: 10271030, 1993. |
|
|
|
|
|
|
|
|
5. L. Gan, P. Hsyu, J. F. Pritchard, and D. Thakker. Mechanism of intestinal absorption of ranitidine and ondansetron transport across Caco-2 cell monolayers. Pharm. Res. 10: 17221725, 1993. |
|
|
|
|
|
|
|
|
6. P. Artursson and J. Karlsson. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (CACO-2) cells. Biochem. Biophys. Res. Comm. 175: 880885, 1991. |
|
|
|
|
|
|
|
|
7. B. Hoener. Predicting the hepatic clearance of xenobiotics in humans from in vitro data. Biopharm. Drug Disposit. 15: 295304, 1994. |
|
|
|
|
|
|
|
|
8. R. L. Kunka, J. R. Ekcardt, J. Verweij, S. P. DePee, D. Littlefield, K. A. Selinger, P. Beranek, P. Collis, and P. S. Wissel. Use of pharmacokinetics as a tool in predicting toxicity of GG211, a new topoisomerase I inhibitor. Clin. Pharmacol. Ther. 57: 175a, 1995. |
|
|
|
|
|
|
|
|
9. T. D. Egan, C. F. Minto, H. J. M. Lemmens, D. J. Hermann, K. T. Muir, and S. L. Shafer. Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. Anesthesiology, in press. |
|
|
|
|
|
|
|
|
10. C. DiPadova, R. Roine, M. Frezza, R. T. Gentry, E. Baraona, and C. S. Lieber. Effects of ranitidine on blood alcohol levels after ethanol ingestion. JAMA 267: 8386, 1992. |
|
|
|
|
|
|
|
|
11. A. Bye, L. F. Lacey, S. Gupta, and J. R. Powell. Effect of ranitidine hydrochloride (150 mg bd) on the pharmacokinetics of increasing doses of ethanol (0.15, 0.3, 0.6 g/kg-L). Brit. J. Clin. Pharmacol., in press. |
|
|
|
|
|
|
|
|
12. S. K. Gupta, E. H. Ellinwood, K. T. Muir, S. Hege, C. Kleoudis, and J. R. Powell. Ethanol pharmacodynamics at low blood concentrations.Am. J. Therapeut. 3: 18, 1995. |
|
|
|
|
|
|
|
|
13. K. R. Sweeney, P. Hsyu, P. Statkevich, and D. R. Taft. Renal disposition and drug interaction screening of (-)-2'-deoxy-3'-thiacytidine (3TC) in the isolated perfused rat kidney. Pharm. Res. 12: 19581963, 1995. |
|
|
|
|
|
|
|
|
14. K. H. P. Moore, G. J. Yuen, R. H. Raasch, J. J. Eron, D. Martin, P. K. Mydlow, and E. K. Hussey. Pharmacokinetics of lamivudine administered alone and with trimethoprim/sulfamethoxazole. Clin. Pharmacol. Ther., in press. |
|
|
|
|
|